CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia

Imatinib (IM) is utilized for targeting the BCR–ABL fusion protein and as such, chronic myeloid leukemia (CML) is considered to be a curable disorder for which patients can achieve a long survival. However, 15–20% CML cases end up with IM resistance that will develop into the accelerated stage and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tianzhuo, Wei, Danna, Lu, Tingting, Ma, Dan, Yu, Kunlin, Fang, Qin, Zhang, Zhaoyuan, Wang, Weili, Wang, Jishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2020
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048251/
https://www.ncbi.nlm.nih.gov/pubmed/35494464
http://dx.doi.org/10.1039/c9ra07971h

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048251/
https://www.ncbi.nlm.nih.gov/pubmed/35494464
http://dx.doi.org/10.1039/c9ra07971h

Ejemplares similares